SYNBIOTIC SE/ Key word(s): Strategic Company Decision
SYNBIOTIC strengthens its presence at international events and monitors advances in cannabis research
18.11.2025 / 10:41 CET/CEST
The issuer is solely responsible for the content of this announcement.
SYNBIOTIC strengthens its presence at international events and monitors advances in cannabis research The European medical cannabis and industrial hemp group SYNBIOTIC SE (ISIN | WKN A3E5A5) is entering the final stretch of the year with strategic initiatives: The Group has already participated in the international Talman House Roadshow in London and will be represented at the Equity Capital Forum in Frankfurt. At the same time, SYNBIOTIC points to current scientific findings on the so-called entourage effect and emphasizes the importance of natural full-spectrum approaches to CBD products.SYNBIOTIC at the Talman House Event 2025 in London As part of its ongoing capital market activities, SYNBIOTIC presented itself on 10 November 2025 as a sponsor and participant at the Talman House Event in London. The renowned industry meeting brings together leading players from the cannabis, healthcare and investment sectors to discuss the future of sustainable and innovative markets. SYNBIOTIC used the event to deepen its exchange with international investors and partner companies and to provide insights into the current development of the Group. “Talman House is an excellent platform to bridge innovative European cannabis companies with international capital providers. For SYNBIOTIC, it is a valuable opportunity to strengthen our network and further expand the Group’s visibility,” said Daniel Kruse, Managing Director of SYNBIOTIC. The event also served to continue close collaboration with the intercontinental network – including Hyde Advisory, Bob Hoban, Global Cannabis Network Collective and Golden Eagle Partners.German Equity Capital Forum 2025 SYNBIOTIC will also be represented at the Equity Capital Forum 2025 from 24 to 26 November in Frankfurt. The aim is to demonstrate to institutional investors the positive development of a sector positioned in the areas of “Health Care,” “Food & Beverage,” and “Consumer Goods,” and to present the Group’s strategic developments.Research confirms potential of the entourage effect – SYNBIOTIC focuses on full-spectrum approaches Recent research findings once again highlight the significance of the so-called entourage effect in cannabis products. As reported by the “Pharmazeutische Zeitung” in its 23 October 2025 issue, the interplay of numerous cannabinoids and terpenes decisively influences the effect profile of cannabis. Researchers at the University of Bern show that full-spectrum extracts can have a different, in some cases enhanced, effect compared to isolated individual substances. This confirms SYNBIOTIC’s strategy of utilizing its in-house capabilities for the development and production of full-spectrum cannabis extracts within the Group. These extracts offer enormous potential for future medical applications and new product forms – far beyond today’s use of cannabis flowers. This also applies to full-spectrum CBD products. Beyond the approval of CBD isolate products, SYNBIOTIC will continue to advocate for clear regulatory frameworks in the EFSA Novel Food process. Joscha Krauß, Managing Director of MH medical hemp: “The entourage effect illustrates that nature provides complex mechanisms of action. It is precisely this interplay that defines high-quality CBD products and demonstrates why objective evaluation and research are so important.” MH medical hemp is a subsidiary of the SYNBIOTIC Group.Publisher SYNBIOTIC SE Daniel Kruse CEO Münsterstraße 336 40470 Düsseldorf Germany www.synbiotic.comMedia Rüdiger Tillmann SYNBIOTIC Public Relations Manager Email ruediger.tillmann@synbiotic.com Mobile +49 170 9651451 c/o JOLE.groupAbout SYNBIOTIC SYNBIOTIC is a listed group of companies in the medical cannabis and industrial hemp sector with a buy-and-build investment strategy focussed on Europe. The Group covers the entire value chain from cultivation to production and retail - from the field to shelf. The subsidiaries' core businesses are research and development, production and the commercialisation of medical cannabis, industrial hemp and CBD products. SYNBIOTIC is pursuing a clear pan-European strategy of further expanding its business areas in order to cover the relevant growth markets while minimising risks and increasing opportunities for investors through diversification.18.11.2025 CET/CEST Dissemination of a Corporate News, transmitted by - a service of .
The issuer is solely responsible for the content of this announcement.
The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
View original content:
Language:EnglishCompany:SYNBIOTIC SEMünsterstr. 33640470 DusseldorfGermanyE-mail:office@synbiotic.comInternet:https://www.synbiotic.com/ISIN:WKN:A3E5A5Listed:Regulated Unofficial Market in Berlin, Dusseldorf, Frankfurt, Munich, Tradegate ExchangeEQS News ID:2231716 End of NewsEQS News Service2231716 18.11.2025 CET/CEST Saving the news in databases or any forwarding of the news to third parties in a commercial context or for commercial purposes is only permitted with the prior written consent of EQS Group AG.